ValuEngine Downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) to Hold
Several other brokerages have also recently commented on DCPH. Piper Jaffray Companies boosted their target price on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, June 3rd. They noted that the move was a valuation call. BidaskClub raised Deciphera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 2nd. Zacks Investment Research raised Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 target price on the stock in a report on Monday, August 5th. Deutsche Bank began coverage on Deciphera Pharmaceuticals in a report on Thursday, July 18th. They set a “buy” rating and a $42.00 target price on the stock. Finally, Guggenheim upped their price target on Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. Deciphera Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $43.67.
NASDAQ:DCPH traded up $15.95 during midday trading on Tuesday, hitting $35.90. 10,854,326 shares of the stock were exchanged, compared to its average volume of 291,452. Deciphera Pharmaceuticals has a one year low of $18.55 and a one year high of $42.99. The company has a market cap of $1.44 billion, a P/E ratio of -12.73 and a beta of 2.34. The company’s 50-day moving average price is $22.57. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.26 and a quick ratio of 7.26.
In other Deciphera Pharmaceuticals news, Director Michael Douglas Taylor sold 22,500 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $40.77, for a total value of $917,325.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Daniel Lee Flynn sold 148,107 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $40.92, for a total value of $6,060,538.44. The disclosure for this sale can be found here. Insiders sold 185,607 shares of company stock worth $7,536,409 in the last ninety days. 7.02% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Montreal Can purchased a new position in Deciphera Pharmaceuticals during the 2nd quarter worth approximately $28,000. BNP Paribas Arbitrage SA grew its position in Deciphera Pharmaceuticals by 61,033.3% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after purchasing an additional 1,831 shares in the last quarter. Virtus ETF Advisers LLC grew its position in Deciphera Pharmaceuticals by 17.7% during the 2nd quarter. Virtus ETF Advisers LLC now owns 12,449 shares of the company’s stock worth $281,000 after purchasing an additional 1,871 shares in the last quarter. JPMorgan Chase & Co. grew its position in Deciphera Pharmaceuticals by 89.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after purchasing an additional 1,913 shares in the last quarter. Finally, Tower Research Capital LLC TRC purchased a new position in Deciphera Pharmaceuticals during the 2nd quarter worth approximately $64,000. Hedge funds and other institutional investors own 59.10% of the company’s stock.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Recommended Story: Quiet Period Expirations
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.